Exagen Inc. is a small-cap molecular diagnostics company specializing in proprietary autoimmune testing (Avise® brand) that has demonstrated revenue growth and improving average selling prices but continues to report net losses amid high volatility and analyst optimism for future profitability.
Fact: Exagen Inc. was founded in 2002 by Waneta C. Tuttle and Cole Harris and is headquartered in Carlsbad/Vista, California (approximately 220 employees). It went public via IPO on September 19, 2019, raising $54 million at $14–$16 per share.
Fact: The company develops and commercializes laboratory tests under the AVISE® brand, leveraging proprietary Cell-Bound Complement Activation Products (CB-CAPs) technology for differential diagnosis, prognosis, and monitoring of autoimmune diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).
Interpretation: Exagen positions itself as a targeted provider for the ~5,000 U.S. rheumatologists, integrating diagnostics with potential therapeutic marketing.
Data limitation: Historical details primarily from company disclosures and third-party summaries (e.g., TradingView, MarketBeat); exact founding motivations or early milestones beyond IPO not detailed in recent sources.
Interpretation: Recent activity signals focus on investor outreach and clinical validation amid ongoing commercialization efforts.
Uncertainty: Q2 results (as of analysis date) not yet released; outcomes could impact near-term sentiment.
| Metric | Value/Details |
|---|---|
| 52-Week Range | $2.59 – $12.23 |
| YTD Performance (approx., from Jan 1, 2026 ~$6.08) | Down ~23% to recent levels around mid-2026 |
| Beta (5Y) | 2.03 (high volatility) |
| 52-Week Change | -48.93% |
| Avg. Daily Volume (3-mo) | ~399k shares |
| Short Interest (Jul 2026) | ~4.05% of shares outstanding; increased recently |
Interpretation: High beta and wide range indicate significant price swings typical of small-cap biotech/diagnostics stocks; recent underperformance relative to broader market.
Limitation: Performance data excludes exact current price per guidelines; historical % changes derived from multiple sources (Macrotrends, Yahoo, MarketBeat) as of early August 2026.
| Metric | Value | Notes |
|---|---|---|
| Revenue (TTM) | $68.38M | Quarterly growth (yoy) 11.70% |
| Gross Profit (TTM) | $39.88M | — |
| Net Income (TTM) | -$20.17M | Profit Margin -29.49% |
| EPS (Diluted, TTM) | -$0.90 | — |
| Operating Cash Flow (TTM) | -$13.37M | Negative |
| Cash (mrq) | $21.51M | Cash per share $0.89 |
| Total Debt (mrq) | $27.15M | Debt/Equity 188.10% |
| Book Value per Share (mrq) | $0.60 | — |
| Price/Sales | 1.52 | — |
Fact: Fiscal year ends Dec 31; 2025 sales growth reported ~19.65% in some summaries.
Interpretation: Improving revenue trajectory and ASPs noted in press releases suggest potential path to breakeven (analyst mentions ~2027 at $80M sales, 60% gross margins), but current losses and cash burn persist.
Uncertainty: Reimbursement rates, test adoption, and R&D spend could materially affect future margins; Q2 2026 results pending.
Assumption/Flag: Financials are trailing twelve months as of most recent quarter (3/31/2026); exact Q2 figures unavailable at time of compilation. Data from Yahoo Finance key statistics and cross-referenced sources.
Fact: Consensus rating is Moderate Buy (average score ~2.89 on some scales) to Strong Buy across sources, based on 7–8 analysts (mix of 1 Strong Buy, 7 Buy, 0–1 Sell/Hold in aggregates).
| Metric | Value |
|---|---|
| Average Price Target | $8.57 – $9.00 |
| High Target | $10.00 |
| Low Target | $8.00 |
| Implied Upside (from recent ~$4.5–$4.7 levels) | ~75–92% |
| Latest Notable Action | Roth Capital initiated Buy (June 25, 2026, PT $8.00) |
Interpretation: Analysts highlight revenue acceleration, ASP improvements, and path to profitability as positives.
Uncertainty: Ratings can change rapidly with earnings or clinical data; small analyst coverage (only a few reports in past 90 days) limits breadth.
Interpretation: Direct sales channel to specialists enables targeted adoption of Avise panels (CTD, Lupus, Sjögren’s).
| Company (Ticker) | Focus Area | Market Cap (approx.) | Notes |
|---|---|---|---|
| Biodesix (BDSX) | Diagnostics & Research | ~$229M | Lung/oncology diagnostics |
| Personalis (PSNL) | Diagnostics & Research | ~$300M+ | Genomic testing |
| Myriad Genetics (MYGN) | Diagnostics | Smaller cap | Genetic/hereditary testing |
| Fulgent Genetics (FLGT) | Diagnostics | Smaller cap | Genetic testing |
| Castle Biosciences (CSTL) | Diagnostics | Smaller cap | Oncology/skin diagnostics |
| Qiagen (QGEN) | Broader Diagnostics | Larger (~$9B+) | Molecular diagnostics tools |
Fact: Direct autoimmune-focused peers are limited; larger players (e.g., Quest Diagnostics, LabCorp – not tickered here) offer broader lab services.
Limitation: Competitor list derived from Yahoo comparisons and Seeking Alpha/Barchart mentions; exact competitive overlap (e.g., reimbursement battles) not quantified in sources.